Ashland’s eternight™ biofunctional arrived in April 2026 with one of the most quotable numbers in the 2026 actives season: skin that looks up to four years younger after a month. Read the supplier’s own product page carefully and a second number sits in brackets right beside it — an average of 1.2 years, measured with an AI facial scan tool. Both figures are Ashland’s. The gap between them is the most useful thing about this launch, because it is where a marketing headline and a defensible claim file part company.
Quick answer: what is eternight™ biofunctional?
eternight™ biofunctional is a cosmetic active from Ashland, launched in April 2026, supplied as an Iris pallida root extract in a water, propanediol and glycerin carrier and positioned around night-time skin repair and mitochondrial “longevity” biology. Ashland reports clinical results of up to four years’ reduction in perceived skin age after one month, with an average of 1.2 years, assessed by an AI facial scan tool, plus improvement in eight visible signs of youth on Asian and Caucasian skin. It won Bronze in the Green Ingredient Award at in-cosmetics Global 2026. Ashland has not published a use level or a pH window, so a formulator’s first step is to request the full technical data sheet.
Key takeaways
- What it is: INCI — water (and) propanediol (and) glycerin (and) Iris pallida root extract. Ashland classifies it under its biofunctionals chemistry, not under peptides.
- Principal: Ashland Inc., a US specialty additives and personal care supplier. The iris is grown in France under regenerative agriculture and processed with Ashland’s proprietary PSR™ (plant small RNA) technology.
- The headline number has a bracket: “up to 4 years younger in just one month” is accompanied on Ashland’s own page by “average 1.2 years, using an AI facial scan tool.” Plan the claim around the average, not the maximum.
- The mitopeptide is a mechanism story, not the ingredient: humanin is a real, well-documented mitochondria-derived peptide, but it does not appear in this product’s ingredient declaration. What is supplied is a botanical extract.
- The award was Green, not Actives: eternight took Bronze in the in-cosmetics Global 2026 Green Ingredient Award — recognition of environmental and social impact, not a placement in the Active Ingredient category.
- Missing from public material: recommended use level, pH window, panel size, study design and whether the clinical work was vehicle-controlled. None of that is unusual pre-dossier; all of it is needed before a claim is written.
What Ashland is actually selling
eternight™ biofunctional is an aqueous botanical extract, and the ingredient declaration tells you most of what you need to know about handling it before any data sheet arrives. The INCI listed on Ashland’s product page is water (and) propanediol (and) glycerin (and) iris pallida root extract: a water-phase material carried in two humectant solvents, with no peptide, no polymer and no encapsulation system named in the declaration.
Iris pallida is a familiar plant in fine fragrance, where the rhizome is aged for years to develop orris. Ashland’s material comes from iris grown in France under regenerative agriculture, and the company describes the extraction as a “biomimetic and sustainable mechano-ionic process” that it markets as PSR™ technology — short for plant small RNA. Ashland positions PSR™ as producing a distinct molecular profile from conventional extraction, and applies AI-driven analysis to the resulting profile.
Around that material sits a layer of Ashland’s own vocabulary: Mitobiology™ for the mitochondrial framing, and [3R] longevity science — Rest, Restore, Reverse — for the night-time positioning. Rest maps to the nocturnal repair window, Restore to mitochondrial quality control, Reverse to the visible-ageing endpoints. It is a clean narrative, and it is worth separating from the ingredient itself, because a supplier’s framework is not the same object as a supplier’s data.
The mitopeptide question: humanin is real, but it is not in the bottle
Ashland describes eternight as “the skin-eternity messenger powered by longevity mitopeptide,” and says the active “optimizes skin youth with humanin mitopeptide: the first universal longevity messenger.” That wording deserves precision rather than dismissal, because both halves of it are defensible only if you keep them apart.
Humanin is a genuine and well-characterised molecule. It is a mitochondria-derived peptide encoded within the mitochondrial 16S rRNA region, and it is one of the better-studied members of that family; the Journal of Clinical Investigation and a 2023 systematic review in International Journal of Molecular Sciences both describe its cytoprotective role and its association with healthy ageing, including the frequently-cited observation that circulating humanin is higher in the offspring of centenarians and generally declines with age.
What that literature does not do is establish that a topical botanical extract raises humanin in human skin, or that raising it produces a cosmetic benefit. Ashland is not claiming humanin as an ingredient — the INCI makes clear it is not one — it is claiming humanin biology as the mechanism its extract engages. Those are different statements with different evidence requirements, and the practical consequence for a brand is simple: “with humanin” is not a claim you can put on pack for this material, because humanin is not in the ingredient declaration. “Inspired by mitochondrial longevity research” is honest; “contains the longevity peptide” is not.
The PSR™ platform invites a similar reading. Cross-kingdom regulation by plant small RNAs is an active and genuinely contested area of science — the review literature on horizontal transfer of small RNAs to and from plants sets out both the supporting work and the repeated difficulty in reproducing it in mammalian systems. That does not make PSR™ extraction invalid; it means a supplier’s platform name is a description of a process, and the efficacy case still has to rest on the clinical work, not on the mechanism’s appeal.
How to read “up to four years younger”
The efficacy headline for eternight is that it is “clinically proven to reverse the visible signs of aging, delivering skin that looks up to 4 years younger in just one month.” Ashland’s own page immediately qualifies it: average 1.2 years, using an AI facial scan tool. Suppliers are not always this forthcoming, and the disclosure is to Ashland’s credit — but it changes what a brand can responsibly say.
Three things follow from that bracket.
First, the average is the plannable number. A maximum describes the best responder in a panel; a mean describes what a buyer of the finished product should expect. Under the EU’s Regulation (EU) No 655/2013 common criteria for cosmetic claims, a claim has to be supported by adequate evidence and must not mislead through omission or presentation. “Up to four years” with the mean buried is exactly the presentation problem that regulation addresses.
Second, an AI facial scan is an instrument, not an endpoint. Perceived-age scoring by software is a fast, reproducible-looking measure, but it inherits whatever population the model was trained on, whatever lighting and capture protocol the study used, and whatever the tool actually optimises for. Before a claim is built on it, ask which tool was used, whether it has published validation, how test–retest variation compares to a 1.2-year effect, and whether the result is corroborated by expert clinical grading or instrumental measurement.
Third, the comparator is unstated in public material. Nothing on the public page says whether the one-month result is against baseline or against a vehicle control. A 1.2-year mean improvement against baseline in a study where every panellist also applied a well-formulated cream nightly is a different claim from the same figure against placebo. This is the single question most worth putting to the supplier first.
The same discipline applies to the second efficacy line — improvement across “8 signs of youth on Asian and Caucasian skins: less redness, evenness, brightening, fade of age spots and wrinkles, restored elasticity, firmness and hydration.” Eight endpoints across two ethnic groups is a substantial programme if it was powered for it, and a multiplicity problem if it was not. Ask for the panel sizes per group.
What is published, and what a formulator still has to ask
Ashland publishes the composition and the positioning, and hosts a full compliance library on the product page — ISO 16128 natural-origin calculation, carbon footprint statement, vegan-suitable and halal/kosher status statements, Nagoya and CITES documentation, toxicology summary and product specification. That is a well-stocked regulatory shelf. What it does not include, publicly, are the two numbers a formulator opens a data sheet to find.
| Parameter | Publicly stated by Ashland | What to request |
|---|---|---|
| INCI | Water (and) propanediol (and) glycerin (and) Iris pallida root extract | Confirm ratio of the extract to carrier, for label order and natural-origin maths |
| Recommended use level | Not published | Use level tested in the clinical study, and the minimum effective level |
| pH window | Not published | Stability-verified pH range, and behaviour outside it |
| Addition point / temperature | Not published | Maximum processing temperature and whether cool-down addition is required |
| Preservation | Not published | Compatibility data; an aqueous botanical extract adds nutrient load to the water phase |
| Clinical design | One month; AI facial scan; Asian and Caucasian panels | Panel size, comparator (baseline or vehicle), statistical significance, per-endpoint results |
| Sustainability | Biodegradable, natural, sustainably sourced, vegan; ISO 16128 calculation available | The ISO 16128 natural-origin index figure and the carbon footprint statement |
Even without the data sheet, the carrier tells a formulator something actionable. Water, propanediol and glycerin means a water-phase addition with high water activity and a humectant load that arrives with the active. In a night cream at a meaningful percentage, that glycerin and propanediol contribution has to be accounted for in the overall humectant budget or the texture drifts tacky — a small point that becomes a reformulation when it is discovered at pilot scale rather than at bench. For a broader view of what to verify before the first production run, our checklist of cosmetic product testing before a first batch covers the stability and compatibility work this kind of active usually triggers.
Where it fits in a range
The night positioning is not incidental — it is the merchandising slot the ingredient was built for. The obvious formats are night creams, overnight sleeping masks, night serums and night-phase eye products, and the aqueous carrier makes emulsions and gel-creams the natural home rather than anhydrous balms or oil serums.
Two practical notes. An overnight product carries a real advantage for a botanical extract: no sun exposure during wear, longer contact time, and a consumer who is measuring the product against how their face looks in the morning — a perception-led category that suits a perception-led endpoint. But “night” also raises the bar on sensory. A night cream is worn for eight hours against a pillow, and humectant-heavy actives can read as sticky in exactly the conditions where the consumer notices. Brands developing in this space will find our roundup of OEM moisturiser and face-cream manufacturers in Malaysia a useful starting point for partners who already run night-format emulsions at scale.
Why this launch is worth watching
eternight sits at the intersection of the three things the 2026 actives market has been organising itself around: skin longevity as a category rather than a claim, chronobiology as a merchandising structure, and sustainability credentials as a purchasing filter. Its award confirms the third. At in-cosmetics Global 2026 in Paris, eternight took Bronze in the Green Ingredient Award — behind dsm-firmenich’s ALPAFLOR® NEUROSOOTH (Gold) and Givaudan Active Beauty’s PrimalHyal™ NeuroYouth (Silver) — a category that recognises environmental or social impact.
That distinction matters when a brand writes copy. “Award-winning active” is true; “award-winning for efficacy” is not what this particular award says. The Active Ingredient category at the same show went to RAHN’s CALNEURIN® SENSE, NAEMOS’s SHISOME, and Chemyunion and dsm-firmenich in bronze. Accuracy here is cheap to get right and expensive to get wrong — the same discipline we set out in our guide to clean and sustainable claims in cosmetics OEM.
The longevity framing is the part to watch commercially. Ashland ties eternight to the “12 hallmarks of aging” — a real framework from the ageing-biology literature, and one that is being borrowed across the actives market faster than the topical evidence for it is accumulating. Brands adopting that vocabulary should read our note on what a skin-longevity claim may actually say on a cosmetic label before it reaches artwork. And for the pattern this launch belongs to — established suppliers re-engineering delivery, sourcing or measurement rather than introducing new molecules — it stands alongside Croda’s encapsulated Matrixyl® Neolide™ and Vytrus Biotech’s Toleroxyl™ tolerogen as one of 2026’s more interesting repositionings.
The wider signal is about measurement. If AI perceived-age scanning becomes a standard efficacy instrument in supplier dossiers — and this launch suggests it is heading that way — the industry will need shared expectations about validation, capture protocol and reporting, in the way it eventually developed them for corneometry and expert grading. Right now, each supplier is effectively defining its own.
Useful links
- Ashland — eternight™ biofunctional official product page (principal’s page: INCI, claims, literature and compliance library)
- Ashland — launch announcement for eternight™ biofunctional
- in-cosmetics Global 2026 award winners (RX Global)
- Premium Beauty News — in-cosmetics Global 2026 award results
- Cosmetics Business — Ashland targets skin longevity with mitochondria-inspired innovation
- Journal of Clinical Investigation — mitochondria-derived peptides in aging and healthspan
- EUR-Lex — Regulation (EU) No 655/2013, common criteria for cosmetic claims
Frequently asked questions
Does eternight™ biofunctional contain humanin?
No. The ingredient declaration is water, propanediol, glycerin and Iris pallida root extract — no peptide is listed. Ashland presents humanin biology as the mechanism the extract is designed to engage, not as a component of the material. A brand may reference the research context, but should not state or imply that the peptide is present in the product.
What use level should we formulate at?
Ashland has not published a recommended use level or a pH window on its public product page, so there is no defensible figure to work from yet. Request the technical data sheet and, specifically, the concentration used in the clinical study — efficacy claims travel with the tested level, not with an arbitrary one.
Can we claim “up to four years younger” on pack?
Not without the underlying study, and probably not in that form even with it. The supplier’s own qualification is an average of 1.2 years measured by an AI facial scan tool, and EU Regulation (EU) No 655/2013 requires claims to be supported and not misleading through presentation. A claim built on the mean, with the measurement method disclosed, is far more defensible than one built on the maximum.
What is an AI facial scan tool in a cosmetic efficacy study?
It is software that estimates apparent skin age from a standardised facial image, used as a summary measure of visible ageing. It is a measurement instrument rather than a regulated endpoint, so its value depends entirely on which tool was used, how it was validated, and how tightly image capture was controlled. Treat it as one line of evidence to be corroborated, not as a substitute for clinical grading or instrumental measurement.
What did eternight actually win at in-cosmetics Global 2026?
Bronze in the Green Ingredient Award, a category recognising environmental or social impact, at the Paris edition in April 2026. It was not placed in the Innovation Zone Best Ingredient — Active category, which was won by RAHN AG’s CALNEURIN® SENSE. Copy that says “award-winning” should be accurate about which award.
Is an Iris pallida extract suitable for natural or vegan positioning?
Ashland lists the material as natural, biodegradable, sustainably sourced and vegan-suitable, and publishes an ISO 16128 natural-origin calculation alongside vegan and halal/kosher status statements. Whether it satisfies a specific naturals standard depends on which standard your retailer or market applies and on the full declaration including the carrier — request the ISO 16128 figure and check it against the standard being used rather than relying on the descriptor icons.
Is this a night-only ingredient?
The positioning is night-specific, but nothing in the composition restricts it to night use. The practical reason to keep it in a PM product is commercial rather than chemical: the [3R] narrative, the sleep-repair story and the consumer’s morning assessment all reinforce each other in that slot, and a daytime version would be competing with SPF and antioxidant claims for the same shelf space.
Limitations and sources
This article is based entirely on publicly available material as of 6 September 2026: Ashland’s own product page and launch communications, the published in-cosmetics Global 2026 award results, and peer-reviewed literature on mitochondria-derived peptides and plant small RNAs. OEMHallmark has not tested eternight™ biofunctional, has not seen the technical data sheet or the clinical study report, and has no commercial relationship connected with this ingredient. Every efficacy figure quoted here is Ashland’s, attributed as such. Where a parameter is described as “not published,” that refers to publicly accessible material only — it is normal for use level, pH and full study design to sit behind a supplier’s registration or dossier request.
Update history
6 September 2026 — first published, based on supplier and award material available at that date.